JP2017502939A - 栄養、運動、及び認知発達 - Google Patents
栄養、運動、及び認知発達 Download PDFInfo
- Publication number
- JP2017502939A JP2017502939A JP2016538075A JP2016538075A JP2017502939A JP 2017502939 A JP2017502939 A JP 2017502939A JP 2016538075 A JP2016538075 A JP 2016538075A JP 2016538075 A JP2016538075 A JP 2016538075A JP 2017502939 A JP2017502939 A JP 2017502939A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- exercise program
- cognitive
- vitamin
- children
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000016709 nutrition Nutrition 0.000 title abstract description 21
- 230000008133 cognitive development Effects 0.000 title abstract description 12
- 230000035764 nutrition Effects 0.000 title abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 78
- 230000001149 cognitive effect Effects 0.000 claims abstract description 65
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 24
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 24
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims abstract description 23
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 22
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims abstract description 13
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 13
- 229960003495 thiamine Drugs 0.000 claims abstract description 13
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 12
- 229910052742 iron Inorganic materials 0.000 claims abstract description 12
- 229960004488 linolenic acid Drugs 0.000 claims abstract description 12
- 239000011777 magnesium Substances 0.000 claims abstract description 12
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 12
- 239000011718 vitamin C Substances 0.000 claims abstract description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229930003451 Vitamin B1 Natural products 0.000 claims abstract description 11
- 229930003537 Vitamin B3 Natural products 0.000 claims abstract description 11
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 11
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000010374 vitamin B1 Nutrition 0.000 claims abstract description 11
- 239000011691 vitamin B1 Substances 0.000 claims abstract description 11
- 235000019160 vitamin B3 Nutrition 0.000 claims abstract description 11
- 239000011708 vitamin B3 Substances 0.000 claims abstract description 11
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 11
- 239000011701 zinc Substances 0.000 claims abstract description 11
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 11
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims abstract description 10
- 235000021468 vitamin B8 Nutrition 0.000 claims abstract description 10
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 9
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 9
- 230000004641 brain development Effects 0.000 claims abstract description 8
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims abstract 3
- 230000008449 language Effects 0.000 claims description 15
- 230000015654 memory Effects 0.000 claims description 14
- 230000003925 brain function Effects 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 230000000007 visual effect Effects 0.000 claims description 5
- 230000003931 cognitive performance Effects 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 235000021152 breakfast Nutrition 0.000 claims description 2
- 230000005057 finger movement Effects 0.000 claims 1
- 235000013336 milk Nutrition 0.000 abstract description 10
- 239000008267 milk Substances 0.000 abstract description 10
- 210000004080 milk Anatomy 0.000 abstract description 10
- 210000004556 brain Anatomy 0.000 abstract description 8
- 238000011161 development Methods 0.000 abstract description 7
- 230000018109 developmental process Effects 0.000 abstract description 7
- 230000003111 delayed effect Effects 0.000 abstract description 2
- 230000006399 behavior Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 10
- 230000003930 cognitive ability Effects 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 206010012559 Developmental delay Diseases 0.000 description 6
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000008131 children development Effects 0.000 description 5
- 230000019771 cognition Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 208000015380 nutritional deficiency disease Diseases 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 4
- 230000002996 emotional effect Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 229940090949 docosahexaenoic acid Drugs 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000020209 toddler milk formula Nutrition 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 230000003936 working memory Effects 0.000 description 3
- 206010001488 Aggression Diseases 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 208000002720 Malnutrition Diseases 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- 230000016571 aggressive behavior Effects 0.000 description 2
- 208000012761 aggressive behavior Diseases 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 230000001071 malnutrition Effects 0.000 description 2
- 235000000824 malnutrition Nutrition 0.000 description 2
- 235000020124 milk-based beverage Nutrition 0.000 description 2
- 230000008137 mother child interaction Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000003715 nutritional status Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000008160 pyridoxine Nutrition 0.000 description 2
- 239000011677 pyridoxine Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 206010061291 Mineral deficiency Diseases 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- UDMBCSSLTHHNCD-DGPXGRDGSA-N [(2r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-DGPXGRDGSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000036992 cognitive tasks Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000003050 macronutrient Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008450 motivation Effects 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000036417 physical growth Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B19/00—Teaching not covered by other main groups of this subclass
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B19/00—Teaching not covered by other main groups of this subclass
- G09B19/003—Repetitive work cycles; Sequence of movements
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B5/00—Electrically-operated educational appliances
- G09B5/02—Electrically-operated educational appliances with visual presentation of the material to be studied, e.g. using film strip
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Business, Economics & Management (AREA)
- Educational Administration (AREA)
- Theoretical Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Educational Technology (AREA)
- Physics & Mathematics (AREA)
- Entrepreneurship & Innovation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pediatric Medicine (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
・言語理解指標(VCI)
・視覚空間認知指標(VSI)
・ワーキングメモリ指標(WMI)
・流動性推理指標(FRI)
・処理速度指標(PSI)
・語彙獲得指標(VAI)
・非言語的指標(NVI)
・一般知的能力指標(CAI)
・認知熟達度指標(CPI)
3歳齢〜5歳齢の小児において一般的な認知能力を評価するための臨床試験
試験群:
試験群は、総勢300名の被験者から構成され(うち20%は途中で脱落した)、次の選択基準に該当する3歳齢〜5歳齢の男児又は女児が試験に参加することとなった。
・3歳齢;0〜4歳齢;11歳齢の男児及び女児
・該当する小児の法定代理人からインフォームド・コンセントを取得
・家庭環境における刺激水準がHOME一覧の平均スコア未満である
・DIKNASにより認知発達が正常であるとして選抜
・発育が正常である(zスコアが−2SD〜+2SDである)
介入研究は、本発明によるグローイングアップミルク(Growing−up milk)製品(1日2回;組成については以下の表を参照されたい。)の毎日の摂取を、認知刺激運動(iPadゲーム及びオフラインでの学習アクティビティ)と組み合わせて6か月間行うことから構成される。
本発明の有効性の評価に使用される検査及び方法としては、認知(WPPSI−IV;ASQ−3)、行動/母子相互作用(PICCOLO)、及び自己評価尺度が挙げられる。
検査の終了時に各群を比較したところ、栄養組成物と認知刺激を与えた群が、上述の検査及び質問により評価された認知、行動、及び相互作用の領域でより良好な成績を示した。特に、本発明の栄養組成物と認知刺激を併用した群において、認知及び行動の良好な改善が得られた。
− 本発明の組成物を与えた小児における、注意、学習、理解、言語、論理的思考、記憶、情報処理、及び集中に関連する少なくとも1つの尺度に関する、認知能力の改善を示す結果
− 本発明の組成物を与えた小児における、愛情、反応、励まし、及び教育に関連する少なくとも1つの尺度に関する、保護者・小児間相互作用の改善を示す結果
− コミュニケーション、粗大運動、微細運動、問題解決、及び対人−社会領域に関連する少なくとも1つの尺度に関する、小児発達の改善を示す結果
− 上述の身体測定値により評価される栄養状態の改善を示す結果
− 情動反応、不安/抑うつ、身体的不調の訴え、引きこもり、注意不足、攻撃的行動、及び睡眠障害に関連する少なくとも1つの領域に関する、小児行動の改善を示す結果
Claims (15)
- 小児における認知発達遅延の予防又は治療における使用のための組成物であって、該組成物は、1回分当たり、少なくとも2.2mgの亜鉛、少なくとも2.0mgの鉄、少なくとも40mgのマグネシウム、少なくとも0.2mgのビタミンB1、少なくとも2.6mgのビタミンB3、少なくとも0.25mgのビタミンB6、少なくとも4μgのビタミンB8、少なくとも12.5mgのビタミンC、及び少なくとも0.15gのαリノレン酸を含み、該組成物は、少なくとも週に1回、各回少なくとも10分間実施される作業課題であって、言語スキル、記憶、注意、問題解決スキル及び/又は精神運動スキルのうちの少なくとも1つを刺激する作業課題を含む認知運動プログラムと組み合わせて使用される、組成物。
- 前記運動プログラムは少なくとも週に3回実施される、請求項1に記載の使用のための組成物及び認知運動プログラム。
- 前記運動プログラムは少なくとも1名の他の家族構成員と一緒に実施される、請求項1又は2に記載の使用のための組成物及び認知運動プログラム。
- 前記運動プログラムは母親と一緒に実施される、請求項3に記載の使用のための組成物及び認知運動プログラム。
- 前記運動プログラムは、注意の領域を支援する作業課題、言語の領域を支援する作業課題、記憶の領域を支援する作業課題、問題解決の領域を支援する作業課題、及び精神運動スキルの領域を支援する作業課題のうちの1つ又は複数、少なくとも3つ、又はすべてを含み、注意の領域を支援する作業課題は、隠れた標的対象を探すこと、及び/又は適合する対象を見つけ出すことを含み、言語の領域を支援する作業課題は、物語を対話形式で読むこと、及び物語の特徴を強調することを含み、記憶の領域を支援する作業課題は、提示された視覚資料を記憶すること、及び予め提示された情報に合致する又はそれを補完するものを認識することを含み、問題解決の領域を支援する作業課題は、より小さな対象がどのようにして全体の一部として組み合わさるのかを見ること、及び/又は数値的、空間的及び/又は言語的に作業課題の解決法を見つけ出すことを含み、精神運動スキルの領域を支援する作業課題は、手先の器用さ、目標を達成するための手及び指の動きを引き出す作業課題を含む、請求項1〜4のいずれか一項に記載の使用のための組成物及び認知運動プログラム。
- 前記運動プログラムは、スマートフォン、コンピューター、及び/又はタブレットPCなどの計算装置用のアプリケーションとして提供される、請求項1〜5のいずれか一項に記載の使用のための組成物及び認知運動プログラム。
- 前記作業課題における小児の成績が以前の成績と比較される、請求項1〜6のいずれか一項に記載の使用のための組成物及び認知運動プログラム。
- 前記作業課題における小児の成績が画面に表示され、以前の成績と比較される、請求項6に記載の使用のための組成物及び認知運動プログラム。
- 前記組成物は少なくとも1日に1回摂取される、請求項1〜8のいずれか一項に記載の使用のための組成物及び認知運動プログラム。
- 前記組成物は、午前中に、例えば朝食の一部として摂取される、請求項1〜9のいずれか一項に記載の使用のための組成物及び認知運動プログラム。
- 前記組成物の摂取と前記運動プログラムの実行との間に3時間を超える間隔がない、請求項1〜10のいずれか一項に記載の使用のための組成物及び認知運動プログラム。
- 小児の認知能力の改善における使用のための、請求項1〜11のいずれか一項に記載の使用のための組成物及び認知運動プログラム。
- 小児の学習能力の改善における使用のための、請求項1〜12のいずれか一項に記載の使用のための組成物及び認知運動プログラム。
- 小児における脳の発達の支援における使用のための、及び/又は小児における正常な脳機能の確保における使用のための、請求項1〜13のいずれか一項に記載の使用のための組成物及び認知運動プログラム。
- 1日用量当たり、少なくとも2.2mgの亜鉛、少なくとも2.0mgの鉄、少なくとも40mgのマグネシウム、少なくとも0.2mgのビタミンB1、少なくとも2.6mgのビタミンB3、少なくとも0.25mgのビタミンB6、少なくとも4μgのビタミンB8、少なくとも12.5mgのビタミンC、及び少なくとも0.15gのαリノレン酸を含む組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13196375.3 | 2013-12-10 | ||
EP13196375 | 2013-12-10 | ||
PCT/EP2014/077298 WO2015086719A1 (en) | 2013-12-10 | 2014-12-10 | Nutrition, exercise and cognitive development |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2017502939A true JP2017502939A (ja) | 2017-01-26 |
Family
ID=49917428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016538075A Pending JP2017502939A (ja) | 2013-12-10 | 2014-12-10 | 栄養、運動、及び認知発達 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20160310529A1 (ja) |
EP (1) | EP3082832A1 (ja) |
JP (1) | JP2017502939A (ja) |
CN (1) | CN105813645A (ja) |
AU (1) | AU2014363490A1 (ja) |
CL (1) | CL2016001428A1 (ja) |
MX (1) | MX2016007490A (ja) |
PH (1) | PH12016500914A1 (ja) |
WO (1) | WO2015086719A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11478011B2 (en) | 2015-12-14 | 2022-10-25 | Societe Des Produits Nestle S.A. | Nutritional compositions and infant formula for promoting de novo myealination |
WO2017102719A1 (en) * | 2015-12-14 | 2017-06-22 | Nestec S.A. | Nutritional compositions and infant formulas to promote myelination in the brain |
PT3389407T (pt) * | 2015-12-14 | 2024-01-19 | Nestle Sa | Composição nutricional e fórmula para lactentes para promover mielinização de novo |
US20220313673A1 (en) * | 2019-08-19 | 2022-10-06 | Neuroreserve Inc. | Dietary supplements to ameliorate dietary inadequacies related to brain health or neurodegenerative diseases, and methods to design dietary supplements |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060247153A1 (en) * | 2005-04-29 | 2006-11-02 | Mcmahon Robert J | Method of improving learning and memory in mammals |
EP2258216A1 (en) * | 2009-06-02 | 2010-12-08 | Nestec S.A. | Nutritional Composition for Supporting Brain Development and Function of Toddlers |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1422551A (zh) * | 2001-12-06 | 2003-06-11 | 上海黄金搭档生物科技有限公司 | 儿童及青少年维生素、矿物质营养组合物 |
-
2014
- 2014-12-10 MX MX2016007490A patent/MX2016007490A/es unknown
- 2014-12-10 JP JP2016538075A patent/JP2017502939A/ja active Pending
- 2014-12-10 US US15/103,424 patent/US20160310529A1/en not_active Abandoned
- 2014-12-10 WO PCT/EP2014/077298 patent/WO2015086719A1/en active Application Filing
- 2014-12-10 CN CN201480065681.8A patent/CN105813645A/zh active Pending
- 2014-12-10 EP EP14809655.5A patent/EP3082832A1/en not_active Withdrawn
- 2014-12-10 AU AU2014363490A patent/AU2014363490A1/en not_active Abandoned
-
2016
- 2016-05-18 PH PH12016500914A patent/PH12016500914A1/en unknown
- 2016-06-10 CL CL2016001428A patent/CL2016001428A1/es unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060247153A1 (en) * | 2005-04-29 | 2006-11-02 | Mcmahon Robert J | Method of improving learning and memory in mammals |
EP2258216A1 (en) * | 2009-06-02 | 2010-12-08 | Nestec S.A. | Nutritional Composition for Supporting Brain Development and Function of Toddlers |
Non-Patent Citations (3)
Title |
---|
WARSITO, OKTARINA ET AL.: "Relationship between nutritional status, psychosocial stimulation, and cognitive development in pres", NUTRITION RESEARCH AND PRACTICE, vol. Vol. 6, No. 5, JPN6018026255, 2012, pages pp. 451-457 * |
WHO: "A Critical Link: Interventions for physical growth and psychological development: A Review", WORLD HEALTH ORGANIZATION, JPN6018026258, 1999 * |
厚生労働省: "日本人の食事摂取基準(2010年度版)", 「日本人の食事摂取基準」策定検討会報告書, JPN6018026261, 2009 * |
Also Published As
Publication number | Publication date |
---|---|
EP3082832A1 (en) | 2016-10-26 |
MX2016007490A (es) | 2016-08-19 |
PH12016500914A1 (en) | 2016-06-20 |
CL2016001428A1 (es) | 2017-01-27 |
WO2015086719A1 (en) | 2015-06-18 |
AU2014363490A1 (en) | 2016-06-02 |
CN105813645A (zh) | 2016-07-27 |
US20160310529A1 (en) | 2016-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Emmett et al. | Pregnancy diet and associated outcomes in the Avon Longitudinal Study of Parents and Children | |
Maughan et al. | IOC consensus statement: dietary supplements and the high-performance athlete | |
Drover et al. | Cognitive function in 18-month-old term infants of the DIAMOND study: a randomized, controlled clinical trial with multiple dietary levels of docosahexaenoic acid | |
Oken et al. | Associations of maternal fish intake during pregnancy and breastfeeding duration with attainment of developmental milestones in early childhood: a study from the Danish National Birth Cohort | |
Vardanjani et al. | The Effect of nutrition education on knowledge, attitude, and performance about junk food consumption among students of female primary schools | |
Gupta | Vitamin D deficiency in India: prevalence, causalities and interventions | |
Besharat Pour et al. | Effect of parental migration background on childhood nutrition, physical activity, and body mass index | |
Jensen et al. | Effects of maternal docosahexaenoic acid intake on visual function and neurodevelopment in breastfed term infants | |
Drover et al. | A randomized trial of DHA intake during infancy: school readiness and receptive vocabulary at 2–3.5 years of age | |
Helmizar et al. | Local food supplementation and psychosocial stimulation improve linear growth and cognitive development among Indonesian infants aged 6 to 9 months | |
Kennedy et al. | Cognitive and mood effects of a nutrient enriched breakfast bar in healthy adults: a randomised, double-blind, placebo-controlled, parallel groups study | |
JP2017502939A (ja) | 栄養、運動、及び認知発達 | |
Roset-Salla et al. | Educational intervention to improve adherence to the Mediterranean diet among parents and their children aged 1–2 years. EniM clinical trial | |
Chunda-Liyoka et al. | Healthy pregnancies and essential fats: focus group discussions with Zambian women on dietary need and acceptability of a novel RUSF containing fish oil DHA | |
Müllerová | Public Health and Preventive Medicine | |
Hark et al. | The nurse practitioner's guide to nutrition | |
Galván et al. | Iodine nutritional status in urban and rural Mexican schoolchildren | |
Khan et al. | Nutritional habits of asylum seekers living in communal accomodation in Stuttgart, Germany | |
Gavaravarapu et al. | National Institute of Nutrition: 100 years of empowering the nation through nutrition | |
Purnell et al. | The intergenerational cycle of obesity and its implications for nursing care of childbearing women | |
Pitman et al. | Ready-to-use supplemental food for nutritional supplementation in cystic fibrosis | |
Mariscal-Arcas et al. | Diet quality in pregnancy: A focus on requirements and the protective effects of the Mediterranean diet | |
Karpouzis et al. | Nutritional complementary and alternative medicine for pediatric attention-deficit/hyperactivity disorder | |
Kennedy et al. | Growth and visual information processing in infants in Southern Ethiopia | |
Bergesen | Nutritional habits and attitudes in fitness center users |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171020 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180710 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180926 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190110 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190312 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20190614 |